OBJECTIVE To construct a remotely contactless intelligent sleep monitoring system(RCISMS),which could be used to assist the titration of Mandibular advancement device(MAD)for the patients of obstructive sleep apnea-hypopnea syndrome(OSAHS),and to verify the effectiveness of the system.METHODS RCISMS was constructed by multidisciplinary medical-engineering cooperation of clinical medicine,biosensing technology,and artificial intelligence;And the diagnostic and therapeutic efficacy evaluation of RCISMS was improved through clinical comparative tests.From December 2023 to May 2024,A total of 176 patients who would receive polysomnography(PSG)evaluation were prospectively collected in the Department of Otolaryngology,Beijing Jishuitan Hospital,Capital Medical University.All the patients met the inclusion criteria and underwent synchronized sleep monitoring using RCISMS and PSG.Through repeatedly comparison with the'gold standard'PSG,the intelligent algorithm of Apnea-hypopnea index(AHI)which is the diagnosis and efficacy of OSAHS was improved in RCISMS.The consistency and correlation of the results between RCISMS and PSG were statistically analyzed.RESULTS RCISMS can continuously monitor the patient's natural sleep in a remote,non-direct contact way,and can upload data in real time,analyze and diagnose intelligently,and the results can be distributed to the doctor and the patient simultaneously.Among the parameters monitored by RCISMS,the AHI,lowest peripheral oxygen saturation(LSpO2),mean peripheral oxygen saturation(MSpO?),sleep efficiency,and the proportion of light sleep stage showed strong correlation with the corresponding PSG parameters(all P<0.05).The LSpO2 and the proportion of light sleep stage showed no statistically significant differences between the two monitoring methods.The consistency test between RCISMS and PSG for AHI classification yielded a Kappa value of 0.627(P<0.001),indicating moderate agreement.The efficacy evaluation of RCISMS for MAD treatment assessment demonstrated 73.8%sensitivity and 100%specificity for OSAHS detection,which helped to precisely identify patients who had achieved full recovery at the endpoint of MAD titration.RCISMS demonstrated sensitivities of 73.8%,84.8%,and 92.7%for detecting mild,moderate,and severe OSAHS respectively,with corresponding specificities of 78.4%,91.6%,and 95.9%.This system can objectively reflect therapeutic changes during MAD titration.CONCLUSION This study established the RCISMS,which provided a novel titration procedure for the MAD titration of OSAHS patients,and might potentially overcome existing limitations in current clinical MAD titration procedures.

OBJECTIVE To compare the efficacy of Eustachian tube pressure nebulization and insuffiation system and conventional drugs on acute otitis media of effusion in adults. METHODS Sixty ears of acute otitis media of effusion in our hospital were selected as the research objects. All patients were divided into two groups according to the treatment,which received drug therapy alone and received drug therapy and nebulizer therapy. The course lasted for 7 days. ETS,ETDQ-7,related hearing tests(acoustic immitance and pure tone threshold),and the therapeutic effect were compared among the three groups. RESULTS In drug therapy alone group,6 ears were cured,10 ears were improved,and the total effective rate was 53.3％. In drug therapy and nebulizer therapy group,17 ears were cured,9 ears were improved,and the total effective rate was 86.7％. There were no complications or adverse reactions in all patients. CONCLUSION The effective rate of the patients treated with Eustachian tube pressure nebulization and insuffiation system combined drug therapy was significantly higher than that of drug therapy alone. On the basis of conventional drug therapy combined with eustachian tube pressure nebulization and insuffiation system might can be a new effective choice for acute otitis media of effusion in adults.